Amifampridine Phosphate
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis, MuSK
Conditions
Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
Trial Timeline
Jun 11, 2018 → Aug 5, 2022
NCT ID
NCT03579966About Amifampridine Phosphate
Amifampridine Phosphate is a phase 3 stage product being developed by Catalyst Pharmaceuticals for Myasthenia Gravis, MuSK. The current trial status is terminated. This product is registered under clinical trial identifier NCT03579966. Target conditions include Myasthenia Gravis, MuSK, AChR Myasthenia Gravis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02189720 | Pre-clinical | Completed |
| NCT03579966 | Phase 3 | Terminated |
Competing Products
20 competing products in Myasthenia Gravis, MuSK
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Phase 3 | 77 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 77 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 77 |
| Placebo + CFZ533 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| mycophenolate mofetil [CellCept] + Placebo | Roche | Phase 3 | 77 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 77 |
| inebilizumab + IV Placebo | Amgen | Phase 3 | 76 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 32 |
| Tolebrutininb + Placebo | Sanofi | Phase 3 | 76 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 76 |
| HIZENTRA ® | CSL | Phase 2 | 51 |
| Subcutaneous immunoglobulins | CSL | Phase 1 | 32 |
| Human normal immunoglobulin G (IgG) | CSL | Phase 3 | 76 |
| zilucoplan (RA101495) | UCB | Phase 3 | 74 |